Клиномир в тестовом запуске. Кто с нами с первых дней, получит отметку «С первых дней» в профиле и первым увидит новые возможности сайта.

Зарегистрироваться
Завершено Фаза III Россия

Отилимаб (GSK3196165)

Многоцентровое, долгосрочное, расширенное исследование для оценки безопасности и эффективности GSK3196165 в лечении ревматоидного артрита

Разрешение№ 492 от 10.09.2020
Номер протокола209564
ФазаФаза III
Участников по плану350
Сроки10.09.2020 — 14.01.2024
Страна разработчикаВеликобритания
Начало: 10 сентября 2020Окончание: 14 января 2024
Плановый срок исследования истёк
Статус рассчитан по плановой дате окончания. В реестре указано: «Проводится».

Постоянная ссылка: https://clinomir.ru/trials/permit/ru/492/2020-09-10/

Источник: ГРЛС — Государственный реестр лекарственных средств Минздрава России; ClinicalTrials.gov (U.S. National Library of Medicine); Расчёт Клиномира. Что откуда

Простыми словами

Словарь терминов
  • Фаза III — большое исследование: новый препарат сравнивают со стандартным лечением или плацебо, чтобы доказать пользу и безопасность.
  • Исследование завершено, новых участников не набирают.
  • Возраст участников: от 18 лет. Остальные условия — в блоке «Кто может участвовать».
  • По плану участвуют 350 чел. в стране «Россия».
  • Центров в реестре: 29 в 14 городах. Список — ниже на странице.
  • Плановая дата окончания (01.2024) уже прошла.

Пересказ собран автоматически из данных реестра, без оценки пользы и рисков. Подробно о рисках и пользе рассказывает врач центра перед подписанием согласия.

Кто может участвовать

Возрастот 18 лет
ПолЛюбой
Здоровые добровольцынет
Полный текст критериев (на английском, как в ClinicalTrials.gov) · включение: 5 · невключение: 14

Критерии включения

  • Participants with rheumatoid arthritis who are aged >=18 years at the time of signing informed consent, who have completed one of the qualifying GSK3196165 clinical studies and who, in the opinion of the investigator, may benefit from treatment with GSK3196165.
  • Body weight >=40 kilograms (kg).
  • Male or female participants are eligible to participate as long as they meet the contraceptive eligibility criteria and agree to abide by the contraceptive requirements.
  • Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.
  • For participants on methotrexate (MTX): must be willing to continue treatment with oral folic acid (at least 5 mg/week) or equivalent while receiving MTX (mandatory co-medication for MTX treatment).

Критерии невключения

  • Had study intervention permanently discontinued at any time during a qualifying study except any participant with a new diagnosis of latent Mycobacterium tuberculosis (TB) at the end of study assessment in a qualifying study and currently undertaking or willing to complete at least 4 weeks of anti-TB treatment off study treatment, per world health organization (WHO) or national guidelines prior to re-commencing therapy and complete the remainder of anti-TB treatment while on study.
  • Evidence of latent TB (as documented by a positive QuantiFERON-TB Gold plus test or T-SPOT.TB test, no findings on medical history or clinical examination consistent with active TB, and a normal chest radiograph) except for participants that
  • Are currently undertaking or willing to complete at least 4 weeks of anti-TB therapy off study treatment, as per WHO or national guidelines prior to re- commencing study treatment and agree to complete the remainder of anti-TB treatment while in the study or
  • Had documented evidence of satisfactory anti-TB treatment as per WHO or national guidelines following review by a physician specializing in TB on entry to a qualifying study.
  • Current or previous active TB regardless of treatment.
  • Were temporarily discontinued from study intervention at the time of the final study visit of a qualifying study and, in the opinion of the investigator, participation in the extension study poses an unacceptable risk for the participant's participation.
  • A new cancer or malignancy except for basal and squamous cell carcinoma of the skin or in situ carcinoma of the cervix treated and considered cured by the investigator.
  • Have developed any lymphoproliferative disorder during a qualifying study, such as Epstein Barr Virus (EBV) related lymphoproliferative disorder, or signs and symptoms suggestive of current lymphatic disease.
  • Have significant uncontrolled cardiovascular, cerebrovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematologic, or neuropsychiatric disorders, or abnormal laboratory values that developed during a qualifying study that, in the opinion of the investigator, poses an unacceptable risk for the participant's participation.
  • Participants who are expected to be non-compliant with restrictions on medications and vaccinations prior to the study, during the study or during the 8-week safety follow-up of the study.
  • Participants who are currently participating in any interventional clinical study other than a qualifying GSK3196165 clinical study.
  • Abnormal chest radiograph within the last 12 weeks judged by the investigator as clinically-significant.
  • Pregnant or lactating, or women planning to become pregnant or initiating breastfeeding.
  • History of sensitivity to any of the study treatments, or components thereof or a history of drug or other allergy that, in the opinion of the investigator or Medical Monitor, contraindicates their participation.

Источник: ClinicalTrials.gov, NCT04333147 · запись обновлена в реестре 7 февраля 2024.

Дизайн и результаты

ДизайнРандомизированное, двойное слепое, параллельные группы; цель — лечение
Включено участников (факт, все страны)2 916
Почему остановлено (как в реестре): Study is early terminated due to Limited efficacy demonstrated in the contRAst program does not support a suitable benefit/risk profile for otilimab as a potential treatment for RA. GSK has decided not to progress with regulatory submissions.
Что измеряют — первичные конечные точки (10), вторичных — 16
  • Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and Adverse Events of Special Interest (AESI) — Up to approximately 145 Weeks
  • Change From Baseline in Hematology Parameter of Platelet Count at Week 24 — Baseline (Day 01) and Week 24
  • Change From Baseline in Hematology Parameter of Platelet Count at Week 48 — Baseline (Day 01) and Week 48
  • Change From Baseline in Hematology Parameter of Platelet Count at Week 96 — Baseline (Day 01) and Week 96
  • Change From Baseline in Hematology Parameter of Platelet Count at Week 144 — Baseline (Day 01) and Week 144
  • Change From Baseline in Hematology Parameter of Hemoglobin at Week 24 — Baseline (Day 01) and Week 24
  • Change From Baseline in Hematology Parameter of Hemoglobin at Week 48 — Baseline (Day 01) and Week 48
  • Change From Baseline in Hematology Parameter of Hemoglobin at Week 96 — Baseline (Day 01) and Week 96
  • Change From Baseline in Hematology Parameter of Hemoglobin at Week 144 — Baseline (Day 01) and Week 144
  • Change From Baseline in White Blood Cell (WBC) Count With Differential i.e. Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils at Week 24 — Baseline (Day 01) and Week 24

Цель исследования

RA is a chronic, systemic inflammatory autoimmune disease which requires treatment for a long time period, hence it is important to study the long-term safety and efficacy of the continuous treatment with GSK3196165 over several years. This is a Phase 3, multicenter, parallel group treatment and long-term extension study primarily to assess safety with efficacy assessment as a secondary objective. Adult participants with RA who have completed the treatment phase of a qualifying GSK3196165 clinical studies (Phase 3 studies contRAst 1 (201790: NCT03980483), contRAst 2 (201791: NCT03970837) and contRAst 3 (202018: NCT04134728) and who, in investigator's judgement will benefit from extended treatment with GSK3196165 will be included in this study (contRAst X \[209564: NCT04333147\]). Participants will continue to receive the same background conventional synthetic disease modifying anti-rheumatic drug(s) \[csDMARD(s)\] treatment as they received in their qualifying study. Eligible participants will be enrolled to receive weekly GSK3196165 90 milligrams (mg) or 150 mg by subcutaneous (SC) injection. The anticipated study duration is approximately 4 years which will enable participants to receive treatment with GSK3196165 until it is expected to become commercially available. Approximately 3000 participants from the qualifying studies will participate in this long-term extension study

Области и заболевания

Где проходит

29 центров в 14 городах

Откуда эта информация

Сведения сведены и нормализованы порталом «Клиномир»: названия компаний и центров приведены к одному написанию. Нашли ошибку? Напишите нам — исправим.

Изменения не сохранены

На этой странице есть несохранённые изменения. Если уйти со страницы, они пропадут.